|Bid||40.00 x 100|
|Ask||0.00 x 0|
|Day's Range||71.64 - 72.66|
|52 Week Range||50.57 - 72.79|
|PE Ratio (TTM)||38.04|
|Earnings Date||Feb 14, 2018 - Feb 19, 2018|
|Forward Dividend & Yield||0.42 (0.59%)|
|1y Target Est||73.29|
Categories: Yahoo FinanceGet free summary analysis Zoetis, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Zoetis, Inc. – Pfizer Inc., Merck & Co., Inc., Eli Lilly and Company, Aratana Therapeutics, Inc., Phibro Animal Health Corporation Class A, Kindred Biosciences, Inc., ImmuCell Corporation and Heska ... Read more (Read more...)
Zoetis today announced the launch of Vanguard® CIV H3N2/H3N8, the latest vaccine in the company’s canine influenza virus portfolio. The new bivalent vaccine helps protect dogs against two strains of the virus known to be circulating in the U.S., CIV H3N2 and CIV H3N8.
The Board of Directors of Zoetis Inc. has declared a first quarter 2018 dividend payable to holders of the company’s common stock of $0.126 per share, an increase of 20% from the quarterly dividend rate paid in 2017.
Zoetis Inc (NYSE: ZTS ), a global leader in animal health products , continues to benefit from favorable industry trends — which is attracting the attention of investors and Wall Street analysts. The Analyst ...
Short interest is extremely low for ZTS with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ZTS. The net inflows of $3.77 billion over the last one-month into ETFs that hold ZTS are among the lowest of the last year and appear to be slowing.
In 2017, the PetMed Express (PETS) website attracted ~32.0 million visitors, ~8.0% of whom placed an order for a conversion ratio of ~25.0%.
Categories: Yahoo FinanceGet free summary analysis Our analysis is based on comparing Zoetis, Inc. with the following peers – Pfizer Inc., Merck & Co., Inc., Eli Lilly and Company, Parnell Pharmaceuticals Holdings Ltd., Aratana Therapeutics, Inc., Kindred Biosciences, Inc., Sanofi Sponsored ADR, Phibro Animal Health Corporation Class A, Heska Corporation and ImmuCell Corporation (PFE-US, MRK-US, LLY-US, PARNF-US, ... Read more (Read more...)
NEW YORK, Nov. 09, 2017-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MiMedx ...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Zoetis, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Let’s talk about the popular Zoetis Inc (NYSE:ZTS). The company’s shares received a lot of attention from a substantial price movement on the NYSE in the over the last fewRead More...
Teva Pharmaceutical missed third-quarter earnings estimates and gave weak full-year guidance early Thursday.
Zoetis (ZTS) reported impressive third-quarter results beating estimates on both counts. Revenues were driven by strong demand for companion animal products worldwide.
On a per-share basis, the Parsippany, New Jersey-based company said it had net income of 61 cents. Earnings, adjusted for non-recurring costs and costs related to mergers and acquisitions, came to 65 cents ...
Zoetis Inc. today reported its financial results for the third quarter of 2017 and raised its full year guidance for revenue and net income.
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Zoetis, Inc. a score of 84. Our analysis is based on comparing Zoetis, Inc. with the following peers – Eli Lilly and Company, Pfizer Inc., Merck & Co., Inc., Parnell Pharmaceuticals Holdings Ltd., Aratana Therapeutics, Inc., Heska Corporation, Sanofi Sponsored ADR, ImmuCell Corporation, Phibro Animal Health Corporation ... Read more (Read more...)
Zoetis' (ZTS) top line is expected to be driven by newly launched Apoquel, Simparica and Cytopoint. The approvals of Clavamox and Nexvet are expected to boost sales further.
Kari Firestone, Aureus Asset Management CEO, discusses her health care sector picks. The “Fast Money Halftime Report” traders and CNBC's Meg Tirrell weigh in.